Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

BACKGROUND: Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during th...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Alison C., Matias, Margarida, Boyle, Helen, Escudier, Bernard, Molinier, Alicia, Laguerre, Brigitte, Helissey, Carole, Brachet, Pierre-Emmanuel, Dugué, Audrey Emmanuelle, Mourey, Loic, Coquan, Elodie, Joly, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440993/
https://www.ncbi.nlm.nih.gov/pubmed/28532444
http://dx.doi.org/10.1186/s12885-017-3312-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440993/
https://www.ncbi.nlm.nih.gov/pubmed/28532444
http://dx.doi.org/10.1186/s12885-017-3312-7

Ejemplares similares